Core Viewpoint - Kodiak Sciences Inc. has announced an upsized underwritten public offering of 6,956,522 shares at a price of $23.00 per share, aiming to raise approximately $160 million in gross proceeds before expenses [1]. Company Overview - Kodiak Sciences is a precommercial biotechnology company focused on retinal therapeutics, utilizing its ABC® Platform to develop next-generation retinal medicines aimed at preventing and treating blindness [5]. - The company is currently advancing three late-stage clinical programs, including Tarcocimab and KSI-501 in Phase 3 studies for retinal vascular diseases, and KSI-101 in Phase 3 studies for Macular Edema Secondary to Inflammation [5]. Offering Details - The public offering is expected to close on or about December 18, 2025, subject to customary closing conditions [1]. - Kodiak Sciences has granted underwriters a 30-day option to purchase an additional 1,043,478 shares at the public offering price [1]. - The offering is conducted under a shelf registration statement previously filed with the SEC, which was declared effective on June 2, 2023 [3].

Core Viewpoint - Kodiak Sciences Inc. has initiated an underwritten public offering of 6,000,000 shares of its common stock, with an option for underwriters to purchase an additional 900,000 shares [1][2]. Company Overview - Kodiak Sciences is a precommercial biotechnology company focused on retinal therapeutics, aiming to develop transformative treatments for leading causes of blindness globally [5]. - The company utilizes its ABC® Platform, which integrates protein-based and chemistry-based therapies, to advance its research and development efforts [5]. - Kodiak is currently developing three late-stage clinical programs, including Tarcocimab and KSI-501 in Phase 3 studies for retinal vascular diseases, and KSI-101 for Macular Edema Secondary to Inflammation [5]. Offering Details - The proposed public offering is subject to market conditions, and there are no guarantees regarding its completion or the final terms [1]. - The shares are being offered under a shelf registration statement that was declared effective by the SEC on June 2, 2023 [3].